Sign In
NASDAQ:EXAS
EXACT Sciences Corporation Stock News
$61.69
-0.390 (-0.628%)
At Close: Dec 02, 2024
Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript)
12:02pm, Tuesday, 03'rd Dec 2024
Exact Sciences Corporation (NASDAQ:EXAS ) Citi's 2024 Global Healthcare Conference December 3, 2024 8:45 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - EVP, Finance Confere
Exact Sciences and Lil Jon Partner on “Get Low #2” Campaign to Encourage Colon Cancer Screening
09:30am, Monday, 02'nd Dec 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has teamed up with multi-platinum, Grammy award-winning artist Lil Jon on the “Get
Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)
01:24pm, Tuesday, 26'th Nov 2024
Editor's note: The headline of this story was updated to correct an error related to the reported day of the week.
Why Is Exact Sciences Stock Trading Higher On Monday?
12:21pm, Tuesday, 26'th Nov 2024
On Monday, the Centers for Medicare & Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule.
Exact Sciences to Participate in December Investor Conferences
06:00am, Tuesday, 26'th Nov 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
05:35pm, Monday, 25'th Nov 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision O
Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript)
04:07pm, Tuesday, 19'th Nov 2024
Exact Sciences Corporation (NASDAQ:EXAS ) Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - Chief Financial Offic
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
08:10am, Monday, 18'th Nov 2024
Exact Sciences presents new positive evidence backing the development of an MCED test.
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
01:00pm, Wednesday, 13'th Nov 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in
Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap.
11:39am, Sunday, 10'th Nov 2024
This article updates the investment merits of Exact Sciences following its disappointing Q3, 2024 earnings. Recent approval of an improved version of its lead product will not show up in revenues for
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
12:36pm, Wednesday, 06'th Nov 2024
Exact Sciences (EXAS) shares plunged Wednesday after the maker of the Cologuard colon cancer screening test reported widening losses and cut its outlook.
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
10:13am, Wednesday, 06'th Nov 2024
On Tuesday, Exact Sciences Corp. EXAS reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst consensus loss estimate of $0.20.
Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut
08:55am, Wednesday, 06'th Nov 2024
EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international expansion.
U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Wednesday.
Exact Sciences Corporation (EXAS) Q3 2024 Earnings Call Transcript
09:06pm, Tuesday, 05'th Nov 2024
Exact Sciences Corporation (NASDAQ:EXAS ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Erik Holznecht - Director, Investor Relations Kevin Conroy - Chairman and CE
